Peptides AcademyPeptides for Fat Loss & Body Recomposition
The peptide conversation around fat loss has shifted entirely since the GLP-1 era. This page separates the clinically validated agents from the research-peptide landscape and explains where each fits.
How peptide Targets Peptides for Fat Loss
Pharmacologic fat loss with peptides works through three mechanisms: appetite suppression via central GLP-1 receptors (semaglutide, tirzepatide, liraglutide), visceral adipose mobilization via GHRH-driven GH elevation (tesamorelin, CJC-1295), and lipolytic or mitochondrial biasing via niche agents (AOD-9604, MOTS-c, 5-amino-1MQ).
The clinically dominant path is GLP-1/GIP agonism — semaglutide and tirzepatide have 15–22% mean weight reduction in controlled trials and are FDA-approved for this indication. Everything else operates at substantially lower magnitudes and with thinner evidence.
For visceral-fat-specific reduction, tesamorelin has the strongest data: the 26-week phase-3 program showed ~15% VAT reduction in HIV lipodystrophy and subsequent research extends this to non-HIV metabolic populations. The GHS approach is slower and more targeted to visceral depots than GLP-1s.
Research peptides like AOD-9604 (a fragment of GH 176-191 proposed to mimic GH's lipolytic activity) and 5-amino-1MQ (a non-peptide NNMT inhibitor often grouped with peptides) have interesting preclinical data but sparse human evidence.
Recommended Peptides (4)
CJC-1295 + Ipamorelin
Research-Grade
The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.
Semaglutide
Ozempic / Wegovy / Rybelsus
Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.
Tesamorelin
Egrifta
FDA-approved synthetic GHRH analog indicated for HIV-associated lipodystrophy, studied for visceral adipose tissue reduction and cognitive endpoints.
Tirzepatide
Mounjaro / Zepbound
First-in-class dual GIP/GLP-1 receptor agonist — SURMOUNT trials showed ~20% mean weight reduction and superior A1c control versus semaglutide.
Frequently Asked Questions
Semaglutide or tirzepatide — which for fat loss?
Do GHS peptides like CJC-1295+Ipamorelin cause meaningful fat loss?
Other peptide Skin Concerns
Peptides for Anti-Aging
Anti-aging is the loosest indication in the peptide literature. 'Longevity' claims are typically ove…
Peptides for Cognitive Function
The cognitive peptide space is dominated by Russian-developed compounds (Semax, Selank, Cerebrolysin…
Peptides for Hair Growth
The peptide hair-growth literature is dominated by GHK-Cu topical and copper peptide complexes. Sign…
Peptides for Injury Recovery
The regenerative peptide category — BPC-157, TB-500, GHK-Cu — has more preclinical signal than most …
Peptides for Longevity
Longevity peptides carry the most hype-to-evidence gap in the field. Russian bioregulator peptides (…
Peptides for Metabolic Optimization
Metabolic peptides overlap heavily with fat-loss peptides but emphasize different endpoints: insulin…
Peptides for Muscle Growth
Hypertrophy-focused peptide protocols cluster around two axes: GH-axis amplification and direct anab…
Peptides for Skin & Glow
Cosmetic peptides have decades of dermatology research. GHK-Cu, Matrixyl, Argireline, and polynucleo…
Peptides for Sleep
The peptide-for-sleep conversation is thinner than marketing implies. DSIP is the only dedicated sle…